The Use of Oral Relugolix in Prostate Cancer

by admin_63069 | May 12, 2023 | Related Topics

“What we noticed is that even though it’s not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables,” says Jason M. Hafron, MD.

What’s New

Decipher Genomic Classifier Shows Prognostic Value in Intermediate-Risk Prostate Cancer
Highlighting Bias and Biological Barriers in Urological Care and Prostate Cancer Research
Impact of Endocrine Disrupting Chemicals on Hormone-Sensitive Cancer
PMSA PET Offers Patients With Prostate Cancer More Precise Diagnosis
Bone Biomarkers Found to be Prognostic for Overall Survival in Prostate Cancer

Disclaimers:

PCSANM provides education, information, and support, not medical advice. Please contact your physician for all your medical concerns. No copyrighted material belonging to others is knowingly used without permission. If any is inadvertently used without permission, please contact our office. Articles are selected from a variety of sources to give as wide a range of content as possible. PCSANM does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.

2533 Virginia St. NE, Suite C Albuquerque, NM 87110

Phone: (505) 254-7784
Toll Free: (800) 278-7678
Fax: (505) 254-7786

Email: pchelp@pcsanm.org